Immunic (IMUX) to Release Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is anticipated to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Immunic Price Performance

IMUX stock opened at $1.15 on Monday. The company has a market capitalization of $103.59 million, a P/E ratio of -0.93 and a beta of 1.89. The company has a 50-day simple moving average of $1.05 and a 200 day simple moving average of $1.24. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11.

Analyst Ratings Changes

Several equities research analysts recently weighed in on IMUX shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Saturday, February 22nd. Finally, D. Boral Capital restated a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $12.67.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.